Literature DB >> 16738192

Is idiopathic pulmonary fibrosis an environmental disease?

Varsha S Taskar1, David B Coultas.   

Abstract

Several sources of evidence, including investigations of pathogenesis and observational studies, support the hypothesis that environmental agents may have an etiologic role in idiopathic pulmonary fibrosis (IPF). Since 1990, six case-control studies have been conducted in three countries and have consistently demonstrated increased risk of IPF with exposures to a number of environmental and occupational agents. In a meta-analysis of these studies, six exposures were significantly associated with IPF (summary odds ratios [95% confidence intervals]), including ever smoking (1.58 [1.27-1.97]), agriculture/farming (1.65 [1.20-2.26]), livestock (2.17 [1.28-3.68]), wood dust (1.94 [1.34-2.81]), metal dust (2.44 [1.74-3.40]), and stone/sand (1.97 [1.09-3.55]). Although there are a number of limitations of the case-control design and these results alone do not establish a causal link, an assessment of all of the available evidence strongly suggests that IPF may be a heterogeneous disorder caused by a number of environmental and occupational exposures.

Entities:  

Mesh:

Year:  2006        PMID: 16738192     DOI: 10.1513/pats.200512-131TK

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  104 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity.

Authors:  Kazuyuki Tsujino; Yoshito Takeda; Toru Arai; Yasushi Shintani; Ryosaku Inagaki; Hiroyuki Saiga; Takeo Iwasaki; Satoshi Tetsumoto; Yingji Jin; Shoichi Ihara; Toshiyuki Minami; Mayumi Suzuki; Izumi Nagatomo; Koji Inoue; Hiroshi Kida; Takashi Kijima; Mari Ito; Masanori Kitaichi; Yoshikazu Inoue; Isao Tachibana; Kiyoshi Takeda; Meinoshin Okumura; Martin E Hemler; Atsushi Kumanogoh
Journal:  Am J Respir Crit Care Med       Date:  2012-05-16       Impact factor: 21.405

3.  Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.

Authors:  Ana L Mora; Mauricio Rojas; Annie Pardo; Moises Selman
Journal:  Nat Rev Drug Discov       Date:  2017-10-30       Impact factor: 84.694

Review 4.  The Role of Aging in Idiopathic Pulmonary Fibrosis.

Authors:  Joseph Leung; Young Cho; Richard F Lockey; Narasaiah Kolliputi
Journal:  Lung       Date:  2015-04-23       Impact factor: 2.584

Review 5.  Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.

Authors:  Justin C Hewlett; Jonathan A Kropski; Timothy S Blackwell
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

Review 6.  Epigenetics in lung fibrosis: from pathobiology to treatment perspective.

Authors:  Britney A Helling; Ivana V Yang
Journal:  Curr Opin Pulm Med       Date:  2015-09       Impact factor: 3.155

7.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 8.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

9.  Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).

Authors:  Dianne M Walters; Kevin M White; Ushma Patel; Martin J Davis; Roberta M Veluci-Marlow; Solomon Raju Bhupanapadu Sunkesula; James C Bonner; Jessica R Martin; Wes Gladwell; Steven R Kleeberger
Journal:  FASEB J       Date:  2013-11-27       Impact factor: 5.191

10.  MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis.

Authors:  Marco Checa; Víctor Ruiz; Martha Montaño; Rafael Velázquez-Cruz; Moisés Selman; Annie Pardo
Journal:  Hum Genet       Date:  2008-10-14       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.